Etiocholanolone

Etiocholanolone (a urinary breakdown product of androgens, the male-type sex hormones) reflects the back end of your steroid metabolism, after hormones like testosterone and DHEA have done their work and your liver has begun processing them out. The amount that shows up in your urine reflects how much hormone is moving through one specific breakdown path, the 5-beta reductase branch of the classic androgen pathway.

This is a research-stage marker without universally agreed clinical cutpoints. Its value sits less in any single number and more in the patterns it reveals when read alongside a sibling metabolite called androsterone, and in how those patterns shift over time as your hormone biology changes.

How This Metabolite Reflects Hormone Metabolism

Androgens like testosterone and DHEA do not simply disappear after circulating in the blood. Your liver pulls them in, attaches small chemical tags, and breaks them down into inactive end products that exit through the urine. Etiocholanolone is the 5-beta reduced end product of this classic pathway. Its sister metabolite is androsterone, which is chemically almost identical but bent in a different shape (5-alpha vs 5-beta, referring to whether the molecule's ring junction sits on one side or the other), giving it different biological behavior. The key point: etiocholanolone specifically tracks the 5-beta reduced fraction of androgen breakdown, not total androgen flux.

Because etiocholanolone arises almost entirely from this classic route, researchers use it as a reference point. The ratio of androsterone to etiocholanolone (often written An/Et) is a standard way to estimate the activity of an enzyme called 5-alpha reductase, which steers androgens toward more potent forms like DHT. Androsterone and etiocholanolone represent competing metabolic fates of the same precursors, so their ratio shows which branch your body is favoring rather than how much hormone is moving through overall.

Liver Fibrosis in Fatty Liver Disease

The liver is the primary site of steroid metabolism, so liver disease can disturb the rhythm by which your body processes androgens. In nonalcoholic fatty liver disease (a condition where excess fat accumulates in the liver), a sulfate-tagged form of etiocholanolone in the blood was found to decrease as fibrosis (scarring of the liver) progressed.

The combined ratio of a DHEA-derived intermediate to etiocholanolone-sulfate tracked closely with how advanced the scarring was, suggesting that as the liver struggles, its handling of sex hormones drifts in a recognizable direction. These findings come from a serum-based measurement rather than the urine collection this test uses, so the same effect on your dried urine result has not been directly confirmed. The original paper's stereochemical labeling for etiocholanolone-S is also internally inconsistent, which is another reason to read this finding as suggestive rather than definitive.

What this means for you: an unexplained drop in your etiocholanolone over time, especially alongside elevated liver enzymes or known metabolic risk factors, is a signal worth investigating. A liver-focused workup (including imaging and fibrosis scoring) can clarify whether disturbed steroid handling is reflecting a quiet liver problem.

Bone Density After Menopause

In postmenopausal women, those with osteoporosis showed lower levels of etiocholanolone compared with women who maintained normal bone mineral density. Higher etiocholanolone correlated with stronger bones and with specific patterns in the gut microbes that influence steroid biosynthesis. This evidence rests on a single observational study using serum measurements, not urinary etiocholanolone, so the association in dried urine has not been directly tested and the finding should be treated as preliminary.

If you are postmenopausal and tracking bone health, a low or falling etiocholanolone reading is not enough to act on alone, but it can serve as one more data point that prompts a DEXA scan or a deeper look at hormone status.

Insulin Resistance and the 5-Alpha Reductase Pattern

In children and adolescents with obesity and insulin resistance, the androsterone-to-etiocholanolone ratio was higher than in their metabolically healthy peers, particularly in boys. This shift points to increased 5-alpha reductase activity, an enzyme adjustment the body appears to make in part to reduce the local availability of stress hormones.

A similar pattern appears in polycystic ovary syndrome (PCOS). A meta-analysis of PCOS studies found higher 5-alpha reductase activity in affected women, with the link to insulin resistance holding even after accounting for body weight. The An/Et ratio is one of the main ways this enzyme shift is measured.

What this means for you: an elevated An/Et ratio is not itself a diagnosis, but it is a useful prompt to look harder at insulin and glucose handling. Pairing this result with fasting insulin, HbA1c, and a fasting glucose check builds a more complete picture.

The Backdoor Androgen Pathway

In congenital adrenal hyperplasia caused by 21-hydroxylase deficiency (an inherited enzyme problem that disrupts adrenal hormone production), the body shifts toward an alternative route to make potent androgens, called the backdoor pathway. The An/Et ratio rises when this backdoor pathway is more active, because it produces more androsterone relative to etiocholanolone.

While this finding is most relevant for people with diagnosed adrenal disorders, it illustrates a broader point: shifts in the An/Et ratio carry mechanistic information about which hormone pathways are running. For most readers, this matters as a reason to pay attention to the ratio rather than just the raw number.

Why One Reading Is Not Enough

Hormone metabolism is dynamic. Your output of etiocholanolone is shaped by recent activity, recent meals, sleep, stress, the phase of your cycle if you have one, and many medications. A single reading captures a snapshot of all of these at once, which is part of why this marker is best read as a trend.

Tracking over time also lets you see how your numbers respond to deliberate changes. If you adjust your sleep, training load, weight, or supplement stack, you can retest in three to six months and watch whether your etiocholanolone and An/Et ratio shift in a meaningful direction. A baseline, a follow-up at three to six months if you are actively making changes, and at least annual monitoring thereafter gives you something to act on rather than guess at.

Because there are no universally standardized cutpoints for this marker, your own history is the most reliable yardstick. A reading that would be unremarkable in someone else may be a meaningful drop from your own personal baseline.

What to Do With an Unexpected Result

An out-of-pattern etiocholanolone result is rarely a verdict on its own. It is a prompt to widen the lens. The most useful next steps depend on which other findings cluster around the result.

• Low etiocholanolone with abnormal liver enzymes: consider a fibrosis-focused workup including ALT, AST, GGT, platelets, and elastography or a similar fibrosis score. Looping in a hepatologist is reasonable if multiple markers point the same way.
• High An/Et ratio with metabolic signals: check fasting insulin, HbA1c, fasting glucose, triglycerides, and ApoB. An endocrinologist familiar with PCOS or metabolic syndrome can help if the cluster is consistent.
• Low etiocholanolone after menopause: pair the result with a DEXA bone density scan, vitamin D, and a fuller hormone panel. Talking with a clinician who manages menopause is reasonable if bone risk is a concern.
• Result that does not fit any obvious pattern: retest within three to six months under more controlled conditions (consistent sleep, no recent intense exercise, no acute illness) before reading too much into it.

When Results Can Be Misleading

Several factors can distort a single etiocholanolone reading without changing what is actually happening in your hormone system.

• Recent androgen or pro-hormone use: oral testosterone, DHEA, or androstenedione supplements can sharply raise urinary etiocholanolone within days. Any androgen-containing product taken in the days before testing will inflate your result.
• Certain anti-inflammatory medications: propyphenazone, a nonsteroidal anti-inflammatory drug, has been shown to alter measured urinary concentrations of etiocholanolone and related metabolites by interfering with how the lab prepares the sample. The hormone change is not real, but the number on the report is.
• Acute illness, severe undernutrition, or starvation: prolonged caloric deprivation lowers overall steroid output and shifts the An/Et ratio, an effect linked to the low-T3 state that develops during starvation. Refeeding restores the ratio. A reading taken during or just after acute illness or aggressive dieting is unlikely to reflect your baseline biology.
• Collection errors with dried urine: this test requires saturating a strip at specific times of day. Skipping a collection point, contaminating the strip with hand cream or skin oils, or letting it sit damp before sealing can all distort results.

Thyroid disease can also rebalance how the body breaks down androgens, shifting the relative amounts of androsterone and etiocholanolone. Hyperthyroidism tends to raise the An/Et ratio while hypothyroidism lowers it. If your thyroid status is changing or undertreated, your steroid metabolite picture will move with it.